PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.
PhotonPharma says that Dr. Warren brings more than three decades of experience in biotechnology innovation, vaccine development, and successful entrepreneurship to guide the company's strategic initiatives and growth trajectory.
Most recently, Dr. Warren served in multiple senior leadership roles at Sanofi Vaccines R&D, including head of Innovation, leading a virtual biotech to advance next-generation influenza vaccines, and head of Global Antigen Design, where his group was responsible for antigen designs to advance projects, invigorate an innovative culture, and explore biology and technology interfaces.
Prior to Sanofi, Dr. Warren was CEO and co-founder of VaxDesign Corporation, which he led through its acquisition by Sanofi in 2010. He also co-founded nScrypt Inc, a company specialising in advanced 3D printing and bioprinting systems, and was a managing partner of Sciperio Inc, an innovative high-technology development company.
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Elaris FlexCo signs global licence agreement with Valneva
Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens
Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial
Delonix Bioworks gets IND clearance for DX-104 in China
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
European Commission approves GSK's Arexvy for adults aged 18 and over